Pricing Log in Create free account

Mesoblast Limited (MESO) vs Replimune Group, Inc. (REPL)

Mesoblast Limited and Replimune Group, Inc. are both Biotechnology companies. Mesoblast Limited and Replimune Group, Inc. are of similar size ($1.9B and $1.8B). Replimune Group, Inc. has the higher net margin (0.00% vs −1,091.7%) and the lower return on invested capital (−928.3% vs 0.00%). Across the 13 metrics below, Mesoblast Limited leads on 9 and Replimune Group, Inc. on 4.

Valuation

Metric MESO REPL Biotechnology median
P/E n/m n/m 10.60
P/S 147.54 n/m 9.40
P/B 1.93 11.16 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 147.13 n/m 9.02
Earnings yield (7.87%) (12.86%) (32.88%)
Free cash flow yield (7.62%) (10.75%) (23.13%)

Profitability

Metric MESO REPL Biotechnology median
Gross margin (269.72%) 0.00% 68.51%
Operating margin (826.28%) 0.00% 0.00%
Net margin (1,091.71%) 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity 0.00% (115.80%) (51.96%)
Return on assets 0.00% (71.01%) (46.06%)
Return on invested capital 0.00% (928.27%) 0.00%

Growth

Metric MESO REPL Biotechnology median
Revenue growth (TTM) (26.54%) — 6.76%
EPS growth (last fiscal year) 48.24% (10.10%) 29.88%
Revenue growth, 5-year CAGR 74.39% — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric MESO REPL Biotechnology median
Debt to equity 0.22 0.59 0.00
Current ratio 1.58 7.11 4.97
Net debt to EBITDA (0.67) 0.51 1.01

Dividend

Metric MESO REPL Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric MESO REPL Biotechnology median
Market cap 1.83b 1.90b 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack